Rapport Therapeutics Inc
Rapport Therapeutics Inc (RAPP) Straddle
RAPP straddle scan found 100 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 66.6%.
Read more
Trading a RAPP straddle lets you take a pure volatility position on Rapport Therapeutics Inc without committing to a direction. Rapport Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate RAPP straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on RAPP profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Rapport Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the RAPP straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders.
The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the RAPP straddle is the cleanest expression of that view. Our scanner prices every RAPP straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a RAPP straddle into a catalyst or short a RAPP straddle to harvest decay, the options straddle setups that matter are all in one place.
| May 21, 2027 | 60.00 | $31.30 | 245 | 98% | 66.6% | $91.30 | $28.70 | 0 |
| May 21, 2027 | 55.00 | $28.30 | 245 | 98% | 65.4% | $83.30 | $26.70 | 0 |
| May 21, 2027 | 50.00 | $25.75 | 245 | 98% | 63.7% | $75.75 | $24.25 | 0 |
| Feb 19, 2027 | 75.00 | $39.83 | 154 | 98% | 63.6% | $114.83 | $35.18 | 0 |
| Feb 19, 2027 | 65.00 | $31.75 | 154 | 98% | 63.4% | $96.75 | $33.25 | 0 |
| Feb 19, 2027 | 70.00 | $35.98 | 154 | 98% | 63.1% | $105.98 | $34.03 | 0 |
| May 21, 2027 | 47.50 | $24.70 | 245 | 98% | 62.3% | $72.20 | $22.80 | 0 |
| Feb 19, 2027 | 57.50 | $26.80 | 154 | 98% | 62.2% | $84.30 | $30.70 | 0 |
| Feb 19, 2027 | 60.00 | $28.73 | 154 | 98% | 62.1% | $88.73 | $31.28 | 0 |
| Feb 19, 2027 | 55.00 | $25.55 | 154 | 98% | 61.2% | $80.55 | $29.45 | 0 |
As of September 21, 2026
Find the right straddle before volatility moves
Track RAPP straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→